Novartis’ Entresto Faces Challenge From Natco In India

Natco has launched a cut-price version of sacubitril/valsartan (Novartis' Entresto) on the Indian market and is also believed to have opposed the patent for the heart failure therapy.

Indian currency
ENTRESTO FACES A CHALLENGE IN INDIA

Could Novartis AG be heading for another tough patent battle in India? It may be too early to predict how things will play out, but Natco Pharma Ltd.’s cut-price version of Novartis’ heart failure therapy Entresto (sacubitril/valsartan) has just made its debut on the Indian market, in what appears to be an “at-risk” launch.

The Hyderabad-based company said that it had launched Valsac (valsartan-sacubitril) tablet at an “affordable price”- the 50mg and 100mg strengths...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip